23 Matching Annotations
  1. Sep 2026
  2. pmc.ncbi.nlm.nih.gov pmc.ncbi.nlm.nih.gov
    TQB2618 plus penpulimab, alone or in combination with chemotherapy, for recurrent or metastatic nasopharyngeal carcinoma: a multicentre, two-cohort, phase 2 trial
    1
    Visit annotations in context

    Tags

    Annotators

    URL

    pmc.ncbi.nlm.nih.gov/articles/PMC13530981/
  3. Aug 2026
  4. 54.241.53.176 54.241.53.176
    ccr-26-0347-html.html
    1
    Visit annotations in context

    Tags

    Annotators

    URL

    54.241.53.176/a3f5302504abf4766687251d339d2945fd504095/ccr-26-0347-html.html
  5. Jul 2026
  6. aacrjournals.org aacrjournals.org
    Subtyping-Directed Precision Treatment Refines Traditional One-Size-Fits-All Therapy for HR+/HER2- Breast Cancer
    1
    Visit annotations in context

    Tags

    Annotators

    URL

    aacrjournals.org/cancerres/article/85/20/3983/766091/Subtyping-Directed-Precision-Treatment-Refines
  7. www.sciencedirect.com www.sciencedirect.com
    GABA promotes resistance to immunotherapy in patients with TLS-positive tumors
    1
    Visit annotations in context

    Tags

    Annotators

    URL

    sciencedirect.com/science/article/pii/S153561082600293X
  8. Jun 2026
  9. aacrjournals.org aacrjournals.org
    Durvalumab versus physician's choice chemotherapy in recurrent ovarian clear cell adenocarcinoma (MOCCA/APGOT-OV2/GCGS-OV3): a multicenter, randomized, phase 2 trial
    1
    Visit annotations in context

    Tags

    Annotators

    URL

    aacrjournals.org/clincancerres/article/31/18/3907/764529/Durvalumab-versus-Physician-s-Choice-Chemotherapy
  10. aacrjournals.org aacrjournals.org
    Phase 2, Open-Label, Multicenter Study of Nelitolimod in Combination with Pembrolizumab in Anti–PD-1 Treatment-Naive Advanced Melanoma
    1
    Visit annotations in context

    Tags

    Annotators

    URL

    aacrjournals.org/clincancerres/article/31/19/4070/765503/Phase-2-Open-Label-Multicenter-Study-of
  11. May 2026
  12. www.sciencedirect.com www.sciencedirect.com
    Deciphering the single-cell molecular landscape of ampullary cancer: A rare gastrointestinal malignancy
    1
    Visit annotations in context

    Tags

    Annotators

    URL

    sciencedirect.com/science/article/pii/S2589004226013908
  13. Mar 2026
  14. pmc.ncbi.nlm.nih.gov pmc.ncbi.nlm.nih.gov
    Neoadjuvant nivolumab with or without ipilimumab for cisplatin-ineligible patients with muscle-invasive bladder cancer
    1
    Visit annotations in context

    Tags

    Annotators

    URL

    pmc.ncbi.nlm.nih.gov/articles/PMC12967298/
  15. Feb 2026
  16. www.sciencedirect.com www.sciencedirect.com
    Hi-C for genome-wide detection of enhancer-hijacking rearrangements in routine lymphoid cancer biopsies
    1
    Visit annotations in context

    Tags

    Annotators

    URL

    sciencedirect.com/science/article/pii/S2666979X26000285
  17. Nov 2025
  18. www.sciencedirect.com www.sciencedirect.com
    Prognostic implications of HER2 in ovarian cancer: Associations with homologous recombination deficiency and folate receptor alpha expression
    1
    Visit annotations in context

    Tags

    Annotators

    URL

    sciencedirect.com/science/article/pii/S0090825825010534
  19. Jun 2025
  20. 52.53.155.43 52.53.155.43
    PDF-html.html
    1
    Visit annotations in context

    Tags

    Annotators

    URL

    52.53.155.43/095f1297dc44b7c13374b7a22bd6385cbe7ad75d/PDF-html.html
  21. Apr 2025
  22. www.sciencedirect.com www.sciencedirect.com
    Phase 2 trial of perioperative chemo-immunotherapy for gastro-esophageal adenocarcinoma: The role of M2 macrophage landscape in predicting response
    1
    Visit annotations in context

    Tags

    Annotators

    URL

    sciencedirect.com/science/article/pii/S2666379125001181
  23. Jan 2025
  24. www.sciencedirect.com www.sciencedirect.com
    IBI310 plus sintilimab vs. placebo plus sintilimab in recurrent/metastatic cervical cancer: A double-blind, randomized controlled trial
    1
    Visit annotations in context

    Tags

    Annotators

    URL

    sciencedirect.com/science/article/pii/S2666634024004872
  25. Sep 2024
  26. www.sciencedirect.com www.sciencedirect.com
    Proteogenomic and metabolomic characterization of human glioblastoma
    1
    Visit annotations in context

    Tags

    Annotators

    URL

    sciencedirect.com/science/article/pii/S1535610821000507
  27. May 2024
  28. aacrjournals.org aacrjournals.org
    Niraparib plus Dostarlimab in Pleural Mesothelioma or Non-Small Cell Lung Cancer harboring HRR mutations: interim results of the UNITO-001 phase 2 prospective trial
    1
    Visit annotations in context

    Tags

    Annotators

    URL

    aacrjournals.org/clincancerres/article/30/5/959/734303/Niraparib-plus-Dostarlimab-in-Pleural-Mesothelioma
  29. Feb 2024
  30. 52.53.155.43 52.53.155.43
    delete-html.html
    2
    Visit annotations in context

    Tags

    Annotators

    URL

    52.53.155.43/cf598364e2561e3de494d0af6acdee45e74e56b3/delete-html.html
  31. Oct 2023
  32. www.sciencedirect.com www.sciencedirect.com
    Real-world efficacy and safety of low-dose pembrolizumab in patients with advanced and refractory gynecologic cancers
    1
    Visit annotations in context

    Tags

    Annotators

    URL

    sciencedirect.com/science/article/pii/S0929664623003996
  33. Jun 2023
  34. www.ncbi.nlm.nih.gov www.ncbi.nlm.nih.gov
    A Phase II Trial of Guadecitabine plus Atezolizumab in Metastatic Urothelial Carcinoma Progressing after Initial Immune Checkpoint Inhibitor Therapy
    1
    Visit annotations in context

    Tags

    Annotators

    URL

    ncbi.nlm.nih.gov/pmc/articles/PMC10233355/
  35. Jan 2023
  36. www.ncbi.nlm.nih.gov www.ncbi.nlm.nih.gov
    Case report: Durable response after pembrolizumab in combination with radiation - induced abscopal effect in platinum - refractory metastatic endometrial clear cell carcinoma
    1
    Visit annotations in context

    Tags

    Annotators

    URL

    ncbi.nlm.nih.gov/pmc/articles/PMC9797856/
  37. Oct 2022
  38. www.ncbi.nlm.nih.gov www.ncbi.nlm.nih.gov
    Tumoral PD-L1 does not impact time to treatment discontinuation in EGFR mutated non-small cell lung cancer patients treated with EGFR tyrosine kinase inhibitor—a Danish cohort study
    1
    Visit annotations in context

    Tags

    Annotators

    URL

    ncbi.nlm.nih.gov/pmc/articles/PMC9554682/
  39. Sep 2022
  40. www.ncbi.nlm.nih.gov www.ncbi.nlm.nih.gov
    Correlation between PD-L1 expression and radiomic features in early-stage lung adenocarcinomas manifesting as ground-glass nodules
    1
    Visit annotations in context

    Tags

    Annotators

    URL

    ncbi.nlm.nih.gov/pmc/articles/PMC9513584/
  41. Feb 2022
  42. www.ncbi.nlm.nih.gov www.ncbi.nlm.nih.gov
    PD-L1 expression and patient outcomes in gastrointestinal neuroendocrine neoplasm: a meta-analysis
    1
    Visit annotations in context

    Tags

    Annotators

    URL

    ncbi.nlm.nih.gov/pmc/articles/PMC8798646/